SPECIAL FEATURES

CCR Translations

4295 "License to Kill" Reflects Joint Action of CD4 and CD8 T Cells
Cornelis J.M. Melief
See related article, p. 4508

CCR Perspectives in Drug Approval

4297 Developing Standards for Breakthrough Therapy Designation in Oncology
Sandra J. Horning, Daniel A. Haber, Wendy K.D. Selig, S. Percy Ivy, Samantha A. Roberts, Jeff D. Allen, Ellen V. Sigal, and Charles L. Sawyers
See related article, p. 4305

4305 Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed?
James C. Yao, Funda Meric-Bernstam, J. Jack Lee, and S. Gail Eckhardt
See related article, p. 4297

Molecular Pathways

4309 Molecular Pathways: Reactive Oxygen Species Homeostasis in Cancer Cells and Implications for Cancer Therapy
Veronique Nogueira and Nissim Hay

Reviews

4315 Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology
Charles Ferté, Andrew D. Trister, Erich Huang, Brian M. Bot, Justin Guinney, Frederic Commo, Solveig Sieberts, Fabrice André, Benjamin Besse, Jean-Charles Soria, and Stephen H. Friend

4326 BRAF in Melanoma: Current Strategies and Future Directions
April K.S. Salama and Keith T. Flaherty

HUMAN CANCER BIOLOGY

4335 Regulation of Cell Proliferation and Migration by Keratin19-Induced Nuclear Import of Early Growth Response-1 in Breast Cancer Cells
Ji-hyun Ju, Wonseok Yang, Kyung-min Lee, Sunhwa Oh, KeeSoo Nam, Sarah Shin, Soon Young Shin, Myung Chan Gye, In-Sun Chu, and Incheol Shin

4347 Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, Maja Todorovic, Giulia Mesiano, Franco Picciotto, Alberto Pisacane, Alessandro Zaccagna, Maria Giuseppa Volpe, Susanna Gallo, Daniela Caravelli, Elena Giaccone, Tiziana Venesio, Antonella Balsamo, Ymera Pignochino, Giovanni Grignani, Fabrizio Carnevale-Schianca, Massimo Aglietta, and Dario Sangiolo

4359 Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
Brian D. Furmanski, Shuiying Hu, Ken-ichi Fujita, Lie Li, Alice A. Gibson, Laura J. Janke, Richard T. Williams, John D. Schuetz, Alex Sparreboom, and Sharyn D. Baker

4371 Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Michele Moschetta, Antonio Basile, Arianna Ferrucci, Maria Antonia Frassanito, Luigia Rao, Roberto Ria, Antonio Giovanni Solimando, Nicola Giuliani, Angelina Boccarelli, Fabio Fumarola, Mauro Coluccia, Bernardo Rossini, Simona Ruggieri, Beatrice Nico, Eugenio Maiorano, Domenico Ribatti, Aldo M. Roccaro, and Angelo Vacca
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4383</td>
</tr>
<tr>
<td>4392</td>
</tr>
<tr>
<td>4404</td>
</tr>
</tbody>
</table>
Identification of Promiscuous KIF20A Long Peptides Bearing Both CD4⁺ and CD8⁺ T-cell Epitopes: KIF20A-Specific CD4⁺ T-cell Immunity in Patients with Malignant Tumor

Yusuke Tomita, Akira Yuno, Hirotake Tsukamoto, Satoru Senju, Yasuhiro Kuroda, Masatoshi Hirayama, Atsushi Irie, Kenta Kawahara, Junji Yatsuda, Akinobu Hamada, Hirofumi Jono, Koji Yoshida, Takuya Tsunoda, Hirotugu Kohrogi, Yoshihiro Yoshitake, Yusuke Nakamura, Masanori Shinohara, and Yasuharu Nishimura

See commentary, p. 4295

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer

Stephanie Cardarella, Atsuko Ogino, Mizuki Nishino, Mohit Butaney, Jeanne Shen, Christine Lydon, Beow Y. Yeap, Lynette M. Sholl, Bruce E. Johnson, and Pasi A. Jänne

LETTER TO THE EDITOR

Oncolytic Virotherapy Trials—Letter

Akseli Hemminki, Minna Oksanen, and Maiju Merisalo-Soikkeli

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer


CORRECTION

Correction: MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

ABOUT THE COVER

The cover shows Rad51 foci (red) in pancreatic cancer cells treated with gemcitabine and radiation. Nuclei are stained with DAPI (blue). For details, see the article by Engelke and colleagues on page 4412 of this issue.
Clinical Cancer Research

19 (16)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/16

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.